tbuckley/cabot-search huggingface dataset:
Bloom
Authors: Daniela Matei
Journal: Annals of Internal Medicine (2012)

Ad Libitum21 August 2012BloomDaniela Matei, MDDaniela Matei, MDFrom Indiana University, Indianapolis, IN 46202.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-4-201208210-00016 Audio Reading - “Bloom” Audio. Listen to a reading of "Bloom" by Daniela Matei, MD. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I dressed up in my new tightperfectly tailored brooks brothers skirt I put onmademoiselle perfume blue shadow around my eyestan peep-toe heels beforeheading outI kept my smile the misty pleasant scentthroughout the day I did not flinchsharing my compassionendlessly I shookhands patted shouldersI did not feel pain untilfive o'clockwhen I walked out springwas finally here the balmy windblossoms on every treecancer is pink.Daniela Matei, MDIndiana UniversityIndianapolis, IN 46202 Author, Article, and Disclosure InformationAffiliations: From Indiana University, Indianapolis, IN 46202.Current Author Address: Daniela Matei, MD, Indiana University, 535 Barnhill Drive, Indianapolis, IN 46202; e-mail, [email protected]. PreviousarticleNextarticle Advertisement Audio Reading - “Bloom” Audio. Listen to a reading of "Bloom" by Daniela Matei, MD. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 21 August 2012Volume 157, Issue 4Page: 297KeywordsShoulders ePublished: 21 August 2012 Issue Published: 21 August 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Opening Comments
Journal: Annals of Internal Medicine (1967)

Article1 September 1967Opening CommentsWALSH MCDERMOTT, M.D., F.A.C.P.WALSH MCDERMOTT, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-67-3-39 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhen the needs of society come in head-on conflict with the rights of an individual, someone has to play God. We can avoid this responsibility so long as the power to decide the particular case-in-point is clearly vested in someone else, for example, a duly elected governmental official. But in clinical investigation, the power to determine this issue of "the individual versus society" is clearly vested in the physician. Both the power itself and, above all,our awareness that we are wielding itare increasing every day and can be expected to increase much further. It is this inescapableawareness... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *At the Colloquium the co-chairman elected to open by proceeding directly to the interchanges between the panel and the challengers and omitted the prepared introductory statement now presented here. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byScience and technology issues in spacecraft fire safetyThe Production of BerylliumHigh?, energy flux conserving equilibria for alfv�n waveThe Evolution of Regulatory Influences on Research with Human SubjectsLarge Scale EHD Heat Pipe ExperimentsA study of the motion of electrons during their extraction from an electron synchrotron by means of the ?r=2/3 nonlinear betatron oscillation resonance 1 September 1967Volume 67, Issue 3_Part_2Page: 39-42 ePublished: 1 December 2008 Issue Published: 1 September 1967 PDF downloadLoading ...
Prospective Study of 90 Children Requiring Treatment for Juvenile Myelomonocytic Leukemia or Myelodysplastic Syndrome: A Report From the Children’s Cancer Group
Authors: William G. Woods, Dorothy R. Barnard, Todd A. Alonzo, Jonathan D. Buckley, Nathan Kobrinsky, Diane C. Arthur, Jean Sanders, Steven Neudorf, Stuart Gold, Beverly J. Lange
Journal: Journal of Clinical Oncology (2002)

PURPOSE: We report the first large prospective study of children with myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fashion on Children’s Cancer Group protocol 2891. PATIENTS AND METHODS: Ninety children with JMML, various forms of MDS, or acute myeloid leukemia (AML) with antecedent MDS were treated with a five-drug induction regimen (standard or intensive timing). Patients achieving remission were allocated to allogeneic bone marrow transplantation (BMT) if a matched family donor was available. All other patients were randomized between autologous BMT and aggressive nonmyeloablative chemotherapy. Results were compared with patients with de novo AML. RESULTS: Patients with JMML and refractory anemia (RA) or RA-excess blasts (RAEB) exhibited high induction failure rates and overall remission of 58% and 48%, respectively. Remission rates for patients with RAEB in transformation (RAEB-T) (69%) or antecedent MDS (81%) were similar to de novo AML (77%). Actuarial survival rates at 6 years were as follows: JMML, 31% ± 26%; RA and RAEB, 29% ± 16%; RAEB-T, 30% ± 18%; antecedent MDS, 50% ± 25%; and de novo AML, 45% ± 3%. For patients achieving remission, long-term survivors were found in those receiving either allogeneic BMT or chemotherapy. The presence of monosomy 7 had no additional adverse effect on MDS and JMML. CONCLUSION: Childhood subtypes of MDS and JMML represent distinct entities with distinct clinical outcomes. Children with a history of MDS who present with AML do well with AML-type therapy. Patients with RA or RAEB respond poorly to AML induction therapy. The optimum treatment for JMML remains unknown.
CENTENARIANISM.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’
Authors: P. Schöffski, A. Wozniak, S. Stacchiotti, P. Rutkowski, J.-Y. Blay, L.H. Lindner, S.J. Strauss, A. Anthoney, F. Duffaud, S. Richter, V. Grünwald, M.G. Leahy, P. Reichardt, J. Sufliarsky, W.T. van der Graaf, R. Sciot, M. Debiec-Rychter, T. van Cann, S. Marréaud, M. Lia, T. Raveloarivahy, L. Collette, S. Bauer
Journal: Annals of Oncology (2018)

Ann Oncol 2017; 28: 3000–3008 (doi: 10.1093/annonc/mdx527) In the original version, one of the authors of the above article was listed incorrectly as ‘Paolo Casali’ rather than ‘Silvia Stacchiotti’. This has now been corrected. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’Annals of OncologyVol. 28Issue 12PreviewClear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor crizotinib in patients with advanced or metastatic CCSA. Full-Text PDF Open Archive
Drug-resistant ventricular tachycardia of 62 days' duration successfully treated by direct-current countershock
Authors: T. R. Kilpatrick
Journal: JAMA (1966)

In a case of ventricular tachycardia of 62 days' duration, a 66-year-old man was successfully treated by direct-current countershock. It is believed that this case represents the longest duration on record of ventricular tachycardia in which the patient was successfully treated and able to resume normal activity. The ease with which the rhythm was corrected by direct-current countershock after unsuccessful drug therapy was indeed impressive. Three attacks of ventricular tachycardia during the subsequent nine months were also terminated successfully by direct-current countershock.
The Motion Picture as a Professional Instrument.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Authors: Robin Parihar, Julie Dierksheide, Yan Hu, William E. Carson
Journal: Journal of Clinical Investigation (2002)

The anti-tumor activity of recombinant mAb’s directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets. However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo. We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12. This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes. Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcγRIII) and the IL-12 receptor expressed on NK cells. Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell–derived cytokines with the capacity to augment anti-tumor immunity. These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb’s might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.
FIBROID TUMOR OF OVARY IN A GIRL OF FOURTEEN
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Appropriateness of Tympanostomy Tubes for Children
Authors: Jerome O. Klein
Journal: JAMA (1995)

<h3>To the Editor.</h3> —We are concerned about several aspects of the report by Dr Kleinman and colleagues<sup>1</sup>on use of tympanostomy tubes in children. Children with recurrent acute otitis media who fail antibiotic prophylaxis are appropriately considered for placement of ventilating tubes but were identified as "inappropriate" or "equivocal" in the report. We have identified tube insertion for this indication in our publications,<sup>2</sup>and there is additional convincing evidence to support this usage.<sup>3,4</sup>A recent clinical trial reported in 1992 by Casselbrant and coworkers<sup>5</sup>addressed this question and again supported use of tympanostomy tubes for children with recurrent acute otitis media who fail antibiotic prophylaxis. The rapid emergence of resistant bacteria such as penicillin-resistant<i>Streptococcus pneumoniae</i>during the past few years may make indications for surgical intervention an even more important alternative to antimicrobial treatment and prophylaxis. We participated in the panel convened by Value Health
From the Centers for Disease Control. Surgeon General's Workshop on Health Promotion and Aging: summary recommendations of Physical Fitness and Exercise Working Group
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>QuickStats:</i> Percentage of Deaths from External Causes,* by Age Group<sup /> — United States, 2017
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Age group at death (years) 1-14 <1 All ages ≥65 80 90 100 0 Percentage of deaths * External causes of death include intentional and unintentional injury, poisoning (including drug overdose), and complication of medical or surgical care and are identified with International Classification of Diseases, Tenth Revision codes V01-Y89 and U01-U03.† Deaths for which an age could not be determined are included in "All ages" but are not included among the age groups given.In 2017, 9% of all deaths were due to external causes.The percentage of deaths due to external causes was highest for those aged 15-24 years (79%) and lowest for those aged <1 year (8%) and aged >65 years (3%) at death.Among those aged 1-14 years, 44% of deaths were due to external causes, compared with 54% for those aged 25-44 years and 13% for those aged 45-65 years.
MEDICAL SOCIETY PROCEEDINGS.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FARM ACCIDENTS
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The problem of discrimination in health care priority setting
Authors: D. C. Hadorn
Journal: JAMA (1992)

Increasingly stringent fiscal restrictions on the scope of medical services available to patients have resulted in calls for explicit health care priority setting. Several commentators have called for the application of decision-analytic principles to such efforts, which would assign services priority based on the extent to which they produce preferred health outcomes. The Oregon Medicaid exercise is an example of such a process. An important challenge to these utilitarian efforts is the need to avoid discrimination against people with medical disabilities. Both of the key elements entailed by decision-analytic approaches to priority setting—estimation of outcomes and assignment of values to those outcomes—are vulnerable to charges of discrimination, primarily because both the medical outcomes expected in disabled individuals and the values they place on those outcomes may differ from the general public. Priority-setting efforts must proceed carefully to avoid the appearance (and reality) of discrimination. (<i>JAMA</i>. 1992;268:1454-1459)
Interferon gamma protects against hepatic tumor growth in rats by increasing Kupffer cell tumoricidal activity
Authors: H Karpoff
Journal: Hepatology (1996)

An increasing number of hepatic resections are being performed as potentially curative surgery for malignant liver neoplasms. Hepatectomy and subsequent liver regeneration produce a local environment that enhances growth of microscopic residual tumor. To determine if pretreatment with murine interferon γ (IFN-γ) can protect against such enhanced tumor growth, Buffalo rats were randomized to receive a 3-day treatment of IFN-γ (50,000 U/qD intraperitoneally) or saline. Groups then underwent intrasplenic injection of 10(6) Morris hepatoma cells, followed 1 hour later by sham (control) or partial hepatectomy (PH) of 70%. PH significantly enhanced tumor growth within the liver control, 8 ± 3 nodules per liver; PH, 73 ± 12 nodules per liver; P < .001). This enhancement was attenuated by prior administration of IFN-γ IFN-γ/PH, 16 ± 3; P < .001 vs. PH). Growth factor release and liver regeneration were not affected significantly by pretreatment with IFN-γ. The effect of IFN-γ on tumor growth is associated with a significant enhancement of Kupffer cell (KC)-mediated tumoricidal activity (percentage of specific lysis, 55 ± 10% control, 78 ± 11% IFN-γ, P < .01) but not lymphocyte-mediated tumoricidal activity. Because microscopic residual disease may be present after hepatectomies for cancer, IFN-γ may be useful agent in retarding growth of residual tumors.
ATCT-02PHASE II STUDY OF IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE INPATIENTS WITH A FIRST RECURRENCE OF GLIOBLASTOMA MULTIFORME
Authors: Aoki Tomokazu, Tetsuya Ueba, Jun Takahashi, Shin-Ichi Miyatake, Masao Matsutani
Journal: Neuro-Oncology (2015)
Heart Transplantation
Authors: Helen B. Taussig
Journal: JAMA (1969)

<h3>To the Editor:—</h3> The Baltimore News on Dec 2, 1968, announced that one year after the first cardiac transplant, 95 transplants had been performed, 43 patients were living and 52 had died. The next week the News announced "a milestone in medicine, the 100th cardiac transplant has been performed." Soon, we hope that the news will announce that one patient has lived for one year following cardiac transplant. Alas, that one patient, although he offers hope for the future, is the great exception, for the late mortality following cardiac transplant has been extremely high. Indeed, far higher than indicated by the 54% given in the above figures. As of Dec 6,I have been advised by the American Heart Association that there were 41 patients who had survived surgery more than a month, and of these 41 only 28 survived more than two months, and 17 for longer than three months,